Home > PPAR & PPAR & > Pioglitazone

Pioglitazone

匹格列酮,Glustin,U 72107,Zactos

Pioglitazone是一种选择性过氧化物酶体增殖物激活受体γ激动剂。

目录号
EY0997
EY0997
EY0997
纯度
99.39%
99.39%
99.39%
规格
5 mg
10 mg
50 mg
原价
399
650
1120
售价
399
650
1120
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes. Binding assays have indicated that this activation is due to direct binding of pioglitazone to each subtype. It has been noted that this agent promotes adipocyte differentiation of mesenchymal and preadipocyte stem cell lines In vitro. Additionally, pioglitazone is an inhibitor of NF κB.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Jaakkola T, et al. Basic Clin Pharmacol Toxicol,?006, 99(1), 44-51.
    [2] Cantello, B.C., et al. 1994. J. Med. Chem. 37: 3977-3985.
    [3] Lehmann, J.M., et al. 1995. J. Biol. Chem. 270: 12953-12956.
    [4] Sakamoto, J., et al. 2000. Biochem. Biophys. Res. Commun. 278: 704-711.

    分子式
    C19H20N2O3S    		 分子量
    356.44    		 CAS号
    111025-46-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    20 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00494559 Diabetes Mellitus|Coronary Artery Stenosis Drug: Pioglitazone|Drug: Placebo Korea University Anam Hospital Phase 4 2007-07-01 2016-02-24
    NCT03080480 Chronic Granulomatous Disease Drug: Pioglitazone Children's Hospital of Fudan University Phase 1|Phase 2 2017-04-01 2017-03-14
    NCT01090752 Diabetes|Hypertension Drug: Pioglitazone|Drug: Metformin University Hospital, Geneva|University of Lausanne Hospitals Phase 4 2005-10-01 2010-03-24
    NCT02687425 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drug: Pioglitazone|Drug: imatinib mesylate Meng Li|Tongji Hospital Phase 2 2016-02-01 2016-02-16
    NCT00671515 Depressive Disorder, Major|Metabolic Syndrome X Drug: Pioglitazone Joseph Calabrese, MD|Takeda Pharmaceuticals North America, Inc.|University Hospitals Cleveland Medical Center Phase 2 2008-04-01 2016-11-30
    NCT02697617 Polycystic Kidney Disease Drug: Pioglitazone|Drug: Placebo Indiana University Phase 2 2015-10-01 2016-10-13
    NCT00719381 Cystic Fibrosis Drug: Pioglitazone Paul Beringer|University of Southern California Phase 1 2008-01-01 2012-06-13
    NCT01151670 Brain Neoplasms, Malignant|Brain Neoplasms, Benign|Malignant Meningioma|Glioblastoma Multiforme|Anaplastic Astrocytoma Drug: pioglitazone|Drug: Pioglitazone Wake Forest University Health Sciences Phase 1 2010-08-01 2017-01-17
    NCT01352182 Severe Sepsis|Septic Shock Drug: Pioglitazone hydrochloride Children's Hospital Medical Center, Cincinnati Phase 1|Phase 2 2011-10-01 2017-01-05
    NCT01637935 Diabetes|Bladder Cancer Drug: Pioglitazone Takeda|Kaiser Permanente|Department of Epidemiology at University of Pennsylvania 2004-07-01 2015-12-09
    NCT00811681 Friedreich's Ataxia Drug: pioglitazone|Drug: Placebo Assistance Publique - H么pitaux de Paris Phase 3 2008-12-01 2013-09-02
    NCT01931566 Mild Cognitive Impairment Due to Alzheimer's Disease Drug: Pioglitazone|Drug: Pioglitazone placebo Takeda|Zinfandel Pharmaceuticals Inc. Phase 3 2013-08-01 2017-01-31
    NCT01068444 Hepatitis Drug: Pioglitazone|Drug: placebo Kaohsiung Medical University Chung-Ho Memorial Hospital Phase 2 2009-04-01 2016-04-05
    NCT02958956 Diabetes Mellitus, Type 2, Cancer Drug: Pioglitazone Takeda 1997-01-01 2016-11-12
    NCT01935804 Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders Drug: Pioglitazone|Drug: Metformin King Abdulaziz University Phase 2 2009-01-01 2014-06-16
    NCT00835120 Metabolic Syndrome|Bipolar Depression|Insulin Resistance Drug: Pioglitazone University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|Takeda Pharmaceuticals North America, Inc. Phase 4 2009-03-01 2016-11-30
    NCT00845182 Type 2 Diabetes|Healthy|Impaired Glucose Tolerance Drug: Pioglitazone|Drug: Exenatide|Drug: Pioglitazone and Exenatide The University of Texas Health Science Center at San Antonio Phase 4 2007-06-01 2015-08-08
    NCT01972724 Type II Diabetes Mellitus Drug: Pioglitazone Takeda Phase 4 2014-01-01 2017-01-11
    NCT01882907 Type 2 Diabetes Drug: vildagliptin|Drug: Pioglitazone Pusan National University Hospital Phase 4 2009-12-01 2015-03-04
    NCT02133625 Advanced Solid Tumor|Metastatic Solid Tumor Drug: carboplatin|Drug: pioglitazone Dana-Farber Cancer Institute Phase 1 2011-08-01 2016-05-12
    NCT01001013 Healthy Drug: LC15-0444, Pioglitazone LG Life Sciences Phase 1 2009-02-01 2010-11-30
    NCT00855010 Obesity|Type 2 Diabetes Drug: pioglitazone|Drug: placebo University of Texas Southwestern Medical Center|National Institutes of Health (NIH) 2009-02-01 2016-06-23
    NCT01258322 Peritoneal Dialysis|Pioglitazone|Hypertriglyceridemia|Insulin Resistance|Inflammation Drug: Pioglitazone Huashan Hospital|Baxter Healthcare Corporation 2008-01-01 2010-12-09

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：